Current Report Filing (8-k)
June 09 2017 - 04:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2017
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-22705
|
|
33-0525145
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
12780 El Camino Real, San Diego, California
|
|
92130
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2
(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4
(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 1.01 Entry into a Material Definitive Agreement.
On June 5, 2017, Neurocrine Biosciences, Inc. (the Company) entered into a First Amendment to Amended and Restated Lease (the Lease
Amendment) with Kilroy Realty, L.P. (the Landlord), amending that certain Amended and Restated Lease between the Company and the Landlord, dated November 1, 2011 (the Lease), pursuant to which the Company leases
its principal executive offices located at 12780 El Camino Real, San Diego, CA (the Premises). The Lease Amendment extends the term of the Lease from January 1, 2020 (the date upon which the Lease was due to expire) through
December 31, 2029. Under the Lease Amendment, commencing July 1, 2017, the Company will pay annual rent of $5,094,022, with annual increases each calendar year. Pursuant to the Lease Amendment the lease payments due under the Lease for each of
July, August and September of 2017 shall be abated. The Lease Amendment also provides the Company with a right of first offer to enter into a lease for an adjacent building to the Premises, subject to the currently existing rights of third-parties
in connection with such building. In addition, under the Lease Amendment, the Landlord has agreed to provide the Company with certain specified tenant improvements and to contribute towards the improvement of the Premises lobby. The Lease
Amendment does not constitute the Companys exercise of one of its two options to extend the Lease, and thus the Company retains two
ten-year
options to extend the Lease in accordance with the terms set
forth in the Lease.
The foregoing does not purport to be a complete description of the Lease Amendment, and is qualified in its entirety by reference to
the full text of the Lease Amendment, a copy of which will be filed with the Companys Quarterly Report on Form
10-Q
for the three-month period ended June 30, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Dated: June 8, 2017
|
|
|
|
NEUROCRINE BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
/s/ Darin M. Lippoldt
|
|
|
|
|
Darin M. Lippoldt
|
|
|
|
|
Chief Legal Officer
|
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Mar 2023 to Mar 2024